Results 191 to 200 of about 507,433 (303)
LMO7 Suppresses Tumor‐Associated Macrophage Phagocytosis of Tumor Cells Through Degradation of LRP1
LMO7 in tumor‐associated macrophages suppresses phagocytosis of tumor cells and limits cytotoxic T lymphocytes infiltration, fostering tumor progression. Mechanistically, LMO7 mediates the ubiquitination and degradation of the phagocytic receptor LRP1, impairing its ability to engulf tumor cells and driving macrophages toward an antitumor phenotype ...
Mengkai Li +12 more
wiley +1 more source
Targeting multiple genetic defects of mitochondrial diseases with a single bacterial lipoate protein ligase. [PDF]
Hu Z, Yu J, Liu Z, Jiang M, Zeng AP.
europepmc +1 more source
Why Don't More Mitochondrial Diseases Exhibit Cardiomyopathy? [PDF]
Singh N, Ren M, Phoon CKL.
europepmc +1 more source
ABSTRACT Acute pancreatitis (AP) begins with pancreatic local inflammation, leading to the onset of systemic inflammatory response syndrome (SIRS), followed by compensatory anti‐inflammatory response syndrome (CARS), which causes immune paralysis and higher mortality rate.
Liwei Liu +15 more
wiley +1 more source
Phase separation in mitochondrial fate and mitochondrial diseases. [PDF]
Chen Q +5 more
europepmc +1 more source
Adrenal Dysfunction in Mitochondrial Diseases. [PDF]
Corkery-Hayward M, Metherell LA.
europepmc +1 more source
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He +17 more
wiley +1 more source
Accelerate the discovery of genetic variants in mitochondrial diseases with Variant prIOritization using Latent spAce. [PDF]
Labory J +6 more
europepmc +1 more source
Animal Models of Mitochondrial Diseases Associated with Nuclear Gene Mutations. [PDF]
Averina OA +3 more
europepmc +1 more source
Osteosarcoma is the most common primary bone tumor with limited treatment options and a terrible prognosis. This review provides a comprehensive summary of the recent development of osteoimmunomodulatory implants for post‐operative osteosarcoma treatment, of which the potential utility in evoking durable anti‐osteosarcoma immunity and accelerating bone
Yilong Dong +6 more
wiley +1 more source

